Pathfinders in Biopharma

46 Episodo

1. ECM: Robust End to Year, Despite Previous Volatility

   Publicado: 31/10/2023
2. Biotech Halftime Report: A Winding Road Ahead

   Publicado: 26/9/2023
3. The Urgent Need to Address the Youth Mental Health Landscape

   Publicado: 17/8/2023
4. Website Traffic Reveals Biopharma Sales Trends

   Publicado: 7/8/2023
5. When to Call it Quits: VCs Making Tough Decisions in a Tough Market

   Publicado: 13/7/2023
6. How Biotech M&A is Redefining the Strategic Landscape

   Publicado: 23/6/2023
7. Healthcare Should Get Ready for ‘Fast and Furious’ M&A

   Publicado: 8/6/2023
8. Innovation and Growth: Key Ingredients to Healthcare M&A

   Publicado: 7/6/2023
9. Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?

   Publicado: 2/6/2023
10. Global Blood Therapeutics Commitment to Sickle-Cell Innovation

    Publicado: 22/5/2023
11. Is This the Breakthrough Moment for Genetic Medicine?

    Publicado: 13/4/2023
12. The Hidden Revolution Set to Turn US Healthcare on its Head

    Publicado: 26/1/2023
13. The Big Picture for Biotech

    Publicado: 13/12/2022
14. Why Biopharma Investment Requires a Different Mindset

    Publicado: 22/11/2022
15. The Optimism Behind the Biopharma Market

    Publicado: 3/10/2022
16. Biotech Investors: How to Find Value in a Bear Market

    Publicado: 21/3/2022
17. A call to action: Global Blood Therapeutics on tackling orphan disease

    Publicado: 8/12/2021
18. Ionis: Raising The Bar For ESG

    Publicado: 28/10/2021
19. Biotech and Big Pharma: Blueprint for Successful Partnership

    Publicado: 30/9/2021
20. What’s Material in ESG for Biopharma Firms?

    Publicado: 4/5/2021